Claudia Haydeé Arce-Salinas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claudia Haydeé Arce-Salinas has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Garcilazo-Reyes
Medical Oncology Department, Instituto Nacional de Cancerología, México City, México
1 shared publication- Angélica Riveros-Rosas
Universidad Nacional Autónoma de México, México
1 shared publication C. Castañeda
Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
1 shared publicationC. Ye
Biostatistics, Genentech, South San Francisco, CA, USA
1 shared publication- Carmen Lizette Gálvez-Hernández
Universidad Nacional Autónoma de México
1 shared publication - Christian Oswaldo Acosta Quiroz
Instituto Tecnologico de Sonora
1 shared publication
Latest Publications
- Open Access
- 8 June 2026
- Published by Elsevier in The Breast
- Vol. 88, 104836
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer
- 8 June 2026
- Published by Elsevier in The Breast
- Vol. 88, 104836
Open AccessPrimary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer
- Open Access
- 1 May 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (5) , e250199
Real-world evidence on the use of hospital resources for subcutaneous and intravenous trastuzumab administration in breast cancer patients at a referral public hospital in Mexico
Aim: The availability of subcutaneous (SC) trastuzumab has introduced a practical alternative to traditional intravenous (IV) delivery for HER2-positive breast cancer. Beyond clinical equivalence, the shift toward SC administration offers the possibility of reorganizing workflow, reducing the pressure on infusion units and improving the treatment experience for both patients and healthcare professionals. This study provides real-world evidence from a large public oncology hospital in Mexico City, examining how SC and IV trastuzumab compare in everyday practice with respect to treatment times, resources use and the perceptions of patients and staff. Materials & methods: A prospective time and motion study was conducted to compare the efficiency and operational impact of SC and IV routes of trastuzumab administered as monotherapy in women with HER2-positive breast cancer at a public hospital in Mexico City. Sixty administrations (30 SC and 30 IV) were analyzed, recorded in real time using a digital system specifically developed for this study. The system documented waiting times, preparation, administration and time spent in the treatment room. Resource utilization was estimated based on the average number of supplies required for each route. In addition, patients and healthcare personnel completed structured questionnaires on comfort, satisfaction and overall experience. Results: Treatment using the SC route was noticeably shorter. Compared with the IV route, median chair time and overall procedure duration dropped by close to 94%, and treatment room occupancy decreased by approximately 83%. This route also required fewer materials and avoided the drug loss due to weight-based IV dosing. Patients described the SC injection as more comfortable and less fatiguing, while healthcare professionals noted less physical effort, lower stress levels and a more manageable workflow. Conclusion: In a routine public oncology setting with limited resources, the use of SC trastuzumab was associated with clear advantages in terms of efficiency and the treatment experience while also mitigating the workload of infusion areas. These results provide practical, context-specific evidence that could help healthcare systems to improve the organization of oncology services and make better use of scarce hospital resources.
- 1 May 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (5) , e250199
Open AccessReal-world evidence on the use of hospital resources for subcutaneous and intravenous trastuzumab administration in breast cancer patients at a referral public hospital in Mexico
Aim: The availability of subcutaneous (SC) trastuzumab has introduced a practical alternative to traditional intravenous (IV) delivery for HER2-positive breast cancer. Beyond clinical equivalence, the shift toward SC administration offers the possibility of reorganizing workflow, reducing the pressure on infusion units and improving the treatment experience for both patients and healthcare professionals. This study provides real-world evidence from a large public oncology hospital in Mexico City, examining how SC and IV trastuzumab compare in everyday practice with respect to treatment times, resources use and the perceptions of patients and staff. Materials & methods: A prospective time and motion study was conducted to compare the efficiency and operational impact of SC and IV routes of trastuzumab administered as monotherapy in women with HER2-positive breast cancer at a public hospital in Mexico City. Sixty administrations (30 SC and 30 IV) were analyzed, recorded in real time using a digital system specifically developed for this study. The system documented waiting times, preparation, administration and time spent in the treatment room. Resource utilization was estimated based on the average number of supplies required for each route. In addition, patients and healthcare personnel completed structured questionnaires on comfort, satisfaction and overall experience. Results: Treatment using the SC route was noticeably shorter. Compared with the IV route, median chair time and overall procedure duration dropped by close to 94%, and treatment room occupancy decreased by approximately 83%. This route also required fewer materials and avoided the drug loss due to weight-based IV dosing. Patients described the SC injection as more comfortable and less fatiguing, while healthcare professionals noted less physical effort, lower stress levels and a more manageable workflow. Conclusion: In a routine public oncology setting with limited resources, the use of SC trastuzumab was associated with clear advantages in terms of efficiency and the treatment experience while also mitigating the workload of infusion areas. These results provide practical, context-specific evidence that could help healthcare systems to improve the organization of oncology services and make better use of scarce hospital resources.
- 10 October 2025
- Published by Elsevier in Surgical Oncology
- Vol. 63, 102304
Overall survival improvement with locoregional control in patients with metastatic breast cancer. Single-institution experience
- 10 October 2025
- Published by Elsevier in Surgical Oncology
- Vol. 63, 102304
Overall survival improvement with locoregional control in patients with metastatic breast cancer. Single-institution experience
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400387
Cascade Testing Among Patients With Breast Cancer: Current Situation and Challenges in Latin America
PURPOSE: Breast cancer is a significant public health issue worldwide, with a particularly high impact in Latin America (LATAM). Genetic risk assessment and germline molecular testing for pathogenic variants in actionable genes are established practices for managing breast cancer risk. Cascade testing, genetic testing of at-risk relatives of individuals carrying these variants, provides a pivotal strategy for cancer prevention and early detection. DESIGN: This review examines the status of cascade testing among patients with breast cancer in LATAM, highlighting the barriers to its implementation and identifying opportunities to expand its application in the region. RESULTS: Despite growing awareness of the importance of genetic risk assessment, the adoption of cascade testing remains limited in LATAM. Key barriers include restricted access to genetic services, financial and infrastructural limitations within public health systems, and sociocultural factors. However, locally driven initiatives that integrate genetic counseling into national health systems and emphasize education for health care providers have demonstrated the potential to foster long-term sustainability. The role of artificial intelligence and machine learning in genetic counseling is emerging, offering possible solutions to optimize cascade testing, but further evidence is required to assess their impact across diverse populations. CONCLUSION: The successful integration of cascade testing into Latin American health care systems requires strategies rooted in local initiatives, supported by public policies, and driven by health care professionals committed to changing paradigms in cancer prevention. Sustainable approaches should prioritize capacity-building, equitable access to genetic services, and the empowerment of health care providers to recognize the transformative impact of genetic counseling on patient outcomes. By fostering regionally adapted models, LATAM can enhance hereditary cancer prevention and ultimately reduce breast cancer incidence and mortality.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400387
Cascade Testing Among Patients With Breast Cancer: Current Situation and Challenges in Latin America
PURPOSE: Breast cancer is a significant public health issue worldwide, with a particularly high impact in Latin America (LATAM). Genetic risk assessment and germline molecular testing for pathogenic variants in actionable genes are established practices for managing breast cancer risk. Cascade testing, genetic testing of at-risk relatives of individuals carrying these variants, provides a pivotal strategy for cancer prevention and early detection. DESIGN: This review examines the status of cascade testing among patients with breast cancer in LATAM, highlighting the barriers to its implementation and identifying opportunities to expand its application in the region. RESULTS: Despite growing awareness of the importance of genetic risk assessment, the adoption of cascade testing remains limited in LATAM. Key barriers include restricted access to genetic services, financial and infrastructural limitations within public health systems, and sociocultural factors. However, locally driven initiatives that integrate genetic counseling into national health systems and emphasize education for health care providers have demonstrated the potential to foster long-term sustainability. The role of artificial intelligence and machine learning in genetic counseling is emerging, offering possible solutions to optimize cascade testing, but further evidence is required to assess their impact across diverse populations. CONCLUSION: The successful integration of cascade testing into Latin American health care systems requires strategies rooted in local initiatives, supported by public policies, and driven by health care professionals committed to changing paradigms in cancer prevention. Sustainable approaches should prioritize capacity-building, equitable access to genetic services, and the empowerment of health care providers to recognize the transformative impact of genetic counseling on patient outcomes. By fostering regionally adapted models, LATAM can enhance hereditary cancer prevention and ultimately reduce breast cancer incidence and mortality.
- Open Access
- 2 September 2024
- Vol. 62 (5) , 1-7
[Perceived stress in Mexican patients newly diagnosed with breast cancer].
Cancer diagnosis has been described as a significant factor causing psychological stress, which may increase a vulnerability to develop psychological disorders, decrease quality of life levels and affect the response to cancer treatment. To validate the Newly Diagnosed Breast Cancer Stress Scale (NDBCSS) and to explore the differences concerning clinical and sociodemographic variables. Cross-sectional study. Patients recently diagnosed with breast cancer on the day they received the definitive cancer diagnosis were invited to participate. The Perceived Stress Scale (PSS) and the NDBCSS were completed; the latter previously underwent a validation process into Spanish (reliability, content validity, structure -EFA- and convergent validity). 176 patients participated; their mean age was of 52.8 years. The scale obtained a content validity of 0.53 and reliability of 0.791; the EFA showed 2 factors explaining 42.31% of the variance. Stress levels were 23.05 (PSS) and 13.2 (NDBCSS). Concern about side effects, the progression of the illness and the lack of information were reported as the most critical stressors for these patients. The NDBCSS showed acceptable psychometric properties for its application in Mexican patients and probably for patients with similar personal characteristics and linguistic and cultural contexts. Based on the results, it is possible to design precise interventions addressed to the stressors they face, such as the impact of the disease and the treatment.
- 2 September 2024
- Vol. 62 (5) , 1-7
Open Access[Perceived stress in Mexican patients newly diagnosed with breast cancer].
Cancer diagnosis has been described as a significant factor causing psychological stress, which may increase a vulnerability to develop psychological disorders, decrease quality of life levels and affect the response to cancer treatment. To validate the Newly Diagnosed Breast Cancer Stress Scale (NDBCSS) and to explore the differences concerning clinical and sociodemographic variables. Cross-sectional study. Patients recently diagnosed with breast cancer on the day they received the definitive cancer diagnosis were invited to participate. The Perceived Stress Scale (PSS) and the NDBCSS were completed; the latter previously underwent a validation process into Spanish (reliability, content validity, structure -EFA- and convergent validity). 176 patients participated; their mean age was of 52.8 years. The scale obtained a content validity of 0.53 and reliability of 0.791; the EFA showed 2 factors explaining 42.31% of the variance. Stress levels were 23.05 (PSS) and 13.2 (NDBCSS). Concern about side effects, the progression of the illness and the lack of information were reported as the most critical stressors for these patients. The NDBCSS showed acceptable psychometric properties for its application in Mexican patients and probably for patients with similar personal characteristics and linguistic and cultural contexts. Based on the results, it is possible to design precise interventions addressed to the stressors they face, such as the impact of the disease and the treatment.